Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vertex Pharmaceuticals Incorporated (VRTX)

270.635   2.905 (1.09%) 09-29 09:53
Open: 267.82 Pre. Close: 267.73
High: 270.809 Low: 266.49
Volume: 82,326 Market Cap: 70,491M
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 2,500 full-time employees. The firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The firm's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The firm's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 270.924 - 272.24 272.24 - 273.537
Low: 260.346 - 262 262 - 263.63
Close: 264.643 - 267.286 267.286 - 269.891

Technical analysis

as of: 2020-09-28 4:38:46 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 317.92     One year: 331.07
Support: Support1: 253.97    Support2: 211.30
Resistance: Resistance1: 272.19    Resistance2: 283.45
Pivot: 264.38
Moving Average: MA(5): 266.09     MA(20): 266.81
MA(100): 277.51     MA(250): 244.81
MACD: MACD(12,26): -1.62     Signal(9): -2.26
Stochastic oscillator: %K(14,3): 58.47     %D(3): 47.39
RSI: RSI(14): 49.71
52-week: High: 306.08  Low: 165.23  Change(%): 59.8
Average Vol(K): 3-Month: 128700  10-Days: 131934

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
VRTX has closed below upper band by 29.8%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 28 Sep 2020
Analysts Mean recommendation for Vertex Pharmaceuticals Incorporated (VRTX) was 2.00: Is this the key time? - The InvestChronicle

Mon, 28 Sep 2020
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on the Path to Profitability - The Oracle Dispatch

Mon, 28 Sep 2020
Zacks: Analysts Expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Post $2.29 EPS - MarketBeat

Fri, 25 Sep 2020
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Sell by BidaskClub - MarketBeat

Tue, 15 Sep 2020
Boiling and ready to burst as Vertex Pharmaceuticals Incorporated (VRTX) last month performance was -0.88% - The InvestChronicle

Fri, 11 Sep 2020
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 260
Shares Float (M) 260
% Held by Insiders 0.14
% Held by Institutions 97.83
Shares Short (K) 3,350
Shares Short P. Month (K) 3,360

Stock Financials

EPS 7.920
EPS Est This Year 1.630
EPS Est Next Year 2.890
Book Value (p.s.) 28.910
Profit Margin 38.51
Operating Margin 38.95
Return on Assets (ttm) 15.3
Return on Equity (ttm) 33.1
Qtrly Rev. Growth 62.0
Gross Profit (p.s.) 7.141
Sales Per Share 20.732
EBITDA (p.s.) 8.485
Qtrly Earnings Growth 213.10
Operating Cash Flow (M) 2,640
Levered Free Cash Flow (M) 1,820

Stock Valuations

PE Ratio 33.80
PEG Ratio 0.41
Price to Book value 9.26
Price to Sales 12.91
Price to Cash Flow 26.42

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.